Hims & Hers Health Inc. [NYSE: HIMS] traded at a low on 06/01/21, posting a -8.40 loss after which it closed the day’ session at $13.20. The company report on May 21, 2021 that Hims & Hers Partners With Alex Rodriguez to Launch Blur Stick Concealer.
The CEO and Chairman of A-Rod Corp., early investor in Hims & Hers and baseball legend, has teamed up with Hims to create an all-new skincare product .
Hims & Hers, the multi-specialty telehealth platform focused on providing modern personalized health and wellness experiences to all consumers, has partnered with Alex Rodriguez to launch The Blur Stick – a new skincare solution developed specifically for men. Built to complement fan-favorite Hims products such as the Goodnight Wrinkle Cream and Customized Acne Cream, the new Blur Stick features premium ingredients like jojoba oil and aloe extract packaged in a sleek, travel-friendly tube that glides on quickly and provides long-lasting coverage for a diverse range of skin tones and textures. The Hims Blur Stick ($22) is available in eight unique shades exclusively at www.forhims.com.
The results of the trading session contributed to over 1542913 shares changing hands. Over the past one week, the price volatility of Hims & Hers Health Inc. stands at 9.32% while the volatility over the past one month is 10.18%.
The market cap for HIMS stock reached $2.34 billion, with 183.41 million shares outstanding and 106.18 million shares in the current float. Compared to the average trading volume of 1.77M shares, HIMS reached a trading volume of 1542913 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Hims & Hers Health Inc. [HIMS]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HIMS shares is $14.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HIMS stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Credit Suisse have made an estimate for Hims & Hers Health Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on May 20, 2021. While these analysts kept the previous recommendation, Truist raised their target price to Hold. The new note on the price target was released on April 21, 2021, representing the official price target for Hims & Hers Health Inc. stock. Previously, the target price had yet another raise to $16, while Credit Suisse analysts kept a Neutral rating on HIMS stock.
The Average True Range (ATR) for Hims & Hers Health Inc. is set at 1.07, with the Price to Sales ratio for HIMS stock in the period of the last 12 months amounting to 15.70. The Price to Book ratio for the last quarter was 1.72, with the Price to Cash per share for the same quarter was set at 0.01.
How has HIMS stock performed recently?
Hims & Hers Health Inc. [HIMS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 9.63. With this latest performance, HIMS shares gained by 6.62% in over the last four-week period, additionally plugging by 26.32% over the last 6 months – not to mention a rise of 33.33% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HIMS stock in for the last two-week period is set at 57.45, with the RSI for the last a single of trading hit 60.12, and the three-weeks RSI is set at 54.54 for Hims & Hers Health Inc. [HIMS]. The present Moving Average for the last 50 days of trading for this stock 11.94, while it was recorded at 13.11 for the last single week of trading, and 12.91 for the last 200 days.
Hims & Hers Health Inc. [HIMS]: Deeper insight into the fundamentals
Return on Total Capital for HIMS is now -2.80, given the latest momentum, and Return on Invested Capital for the company is -23.51. Return on Equity for this stock declined to -23.51, with Return on Assets sitting at -19.63.
Reflecting on the efficiency of the workforce at the company, Hims & Hers Health Inc. [HIMS] managed to generate an average of -$222,491 per employee.Hims & Hers Health Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.20 and a Current Ratio set at 0.20.
Insider trade positions for Hims & Hers Health Inc. [HIMS]
There are presently around $937 million, or 58.10% of HIMS stock, in the hands of institutional investors. The top three institutional holders of HIMS stocks are: THRIVE CAPITAL MANAGEMENT, LLC with ownership of 15,303,963, which is approximately New of the company’s market cap and around 0.70% of the total institutional ownership; INSTITUTIONAL VENTURE MANAGEMENT XVI, LLC, holding 9,278,875 shares of the stock with an approximate value of $122.48 million in HIMS stocks shares; and INSTITUTIONAL VENTURE MANAGEMENT XV, LLC, currently with $122.48 million in HIMS stock with ownership of nearly New of the company’s market capitalization.
Positions in Hims & Hers Health Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 71 institutional holders increased their position in Hims & Hers Health Inc. [NYSE:HIMS] by around 67,141,510 shares. Additionally, 31 investors decreased positions by around 5,108,692 shares, while 2 investors held positions by with 1,274,719 shares. The mentioned changes placed institutional holdings at 70,975,483 shares, according to the latest SEC report filing. HIMS stock had 63 new institutional investments in for a total of 64,895,739 shares, while 24 institutional investors sold positions of 4,427,312 shares during the same period.